PSNL

Personalis, Inc.

A cancer genomics company that reads the full DNA of a patient's tumor to help doctors spot cancer returning earlier than scans can. Its flagship test, NeXT Personal, is a liquid biopsy that hunts for tiny traces of tumor DNA in a blood sample. Founded in 2011 by Stanford University researchers, the company's name comes from "personalized" medicine — tailoring cancer care to each patient's unique genetic makeup.

Recent Activity

Show $

2026Q2

1 buy1 sell

ARK Genomic Revolution ETFTRIM

-311.8K shares(-3.7%)

ARK Genomic Revolution ETFTRIM

-311.8K shares(-3.7%)

ARK InvestADD

+327.2K shares(+4.1%)

ARK InvestADD

+327.2K shares(+4.1%)

2026Q1

2 buys1 sell

ARK Genomic Revolution ETFADD

+396.3K shares(+5.0%)

ARK Genomic Revolution ETFADD

+396.3K shares(+5.0%)

ARK InvestADD

+65.0K shares(+0.8%)

ARK InvestADD

+65.0K shares(+0.8%)

Polen Capital ManagementEXIT

-50.7K shares

Polen Capital ManagementEXIT

-50.7K shares

Loading more activity...